Clinical Trial Update: XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating XL092 in metastatic castration-resistant prostate cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• XL092

Snippet

Sponsor: University of Utah | Conditions: Metastatic Castration-resistant Prostate Cancer | Phase 2 | Status: RECRUITING